| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 05/16/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 03/22/2023 | 93.42% | BTIG | $6 → $5 | Maintains | Buy |
| 11/17/2022 | 170.79% | BTIG | $10 → $7 | Maintains | Buy |
| 11/15/2022 | 170.79% | Canaccord Genuity | $8 → $7 | Maintains | Buy |
| 05/13/2022 | 557.64% | Keybanc | $20 → $17 | Maintains | Overweight |
| 03/25/2022 | 673.69% | Keybanc | $30 → $20 | Maintains | Overweight |
| 11/11/2021 | 1060.54% | Keybanc | $33 → $30 | Maintains | Overweight |
| 04/15/2021 | 867.12% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 03/02/2021 | 1176.6% | KeyBanc | $32 → $33 | Maintains | Overweight |
| 11/10/2020 | 1137.91% | Keybanc | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2020 | 596.32% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 06/02/2020 | 673.69% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 11/13/2019 | 867.12% | Cantor Fitzgerald | $18 → $25 | Maintains | Overweight |
| 10/14/2019 | 596.32% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 10/14/2019 | 557.64% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 10/14/2019 | — | William Blair | Initiates Coverage On | → Outperform |
What is the target price for Exagen (XGN)?
The latest price target for Exagen (NASDAQ: XGN) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $6.00 expecting XGN to rise to within 12 months (a possible 132.11% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exagen (XGN)?
The latest analyst rating for Exagen (NASDAQ: XGN) was provided by Cantor Fitzgerald, and Exagen reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating Exagen (XGN) correct?
While ratings are subjective and will change, the latest Exagen (XGN) rating was a reiterated with a price target of $0.00 to $6.00. The current price Exagen (XGN) is trading at is $2.59, which is within the analyst's predicted range.